How GLP-1 Medications Are Transforming Healthcare: Impact on Hospitals, Cardiology, and Pharma Pipeline – News and Statistics

Aug 20, 2026

1 Drugs Reshape Healthcare: Beyond Weight Loss

A panel discussion on Barron’s Roundtable examined the expanding use of GLP-1 medications beyond weight loss, exploring new medical applications, potential side effects, and the implications of the next generation of these drugs for patients

According to a report by Wells Fargo, GLP-1 weight loss drugs are reshaping the healthcare industry by addressing obesity. The report, released on Thursday, notes that much of the American healthcare system has been structured around obesity, given its prevalence: 40.3% of adults are considered obese and 9.4% severely obese

Usage of GLP-1 drugs surged over 140% from 2022 to 2024, significantly impacting hospital services aimed at treating obesity. During the same period, bariatric surgery volumes fell by 34.1%

John Teasley, market executive for Wells Fargo Healthcare Banking, commented that GLP-1s are marketed as weight-loss drugs but are rapidly becoming one of the most disruptive economic forces in healthcare. He noted that this medication class has the potential to reshape how providers generate revenue, where investors allocate capital, and how consumers engage with their health

The report indicates that hospitals are adapting to a changing landscape caused by the rise of GLP-1 semaglutide drugs, as obesity patients who previously might have undergone surgery after diet attempts now have a pharmaceutical alternative that is visible, reversible, and socially normalized

GLP-1s may also impact cardiology. A trial showed that their use reduced major cardiovascular events by 20% in overweight or obese adults without diabetes. If this trend prevails at scale, hospitals could see fewer procedures, repeat admissions, complications, and downstream interventions, leading to a sizable reduction in demand for those services

Other aspects of managing chronic obesity may evolve with increased GLP-1 use, including more longitudinal management, outpatient visits, side effect monitoring, and medication management. This could also affect treatments for obesity-related comorbidities like knee and hip replacements, sleep apnea, and metabolic liver disease

Teasley said the biggest takeaway from their research is not that healthcare is shrinking, but that it is being rewired

The report also highlights that the rise of GLP-1 treatments is reshaping pharmaceutical development strategies. An analysis by Deloitte found that obesity drugs are now the largest component of the late-stage pipeline, surpassing oncology treatments for the first time in 16 years. GLP-1 drugs drove this increase almost exclusively, raising obesity treatments from 1% of the pipeline in 2022 to about 25% now, while oncology slipped to 20% after being at 32% in 2022

1. 1. INTRODUCTION

   Making Data-Driven Decisions to Grow Your Business

   1. REPORT DESCRIPTION
   2. RESEARCH METHODOLOGY AND THE AI PLATFORM
   3. DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
   4. GLOSSARY AND SPECIFIC TERMS

2. 2. EXECUTIVE SUMMARY

   A Quick Overview of Market Performance

   1. KEY FINDINGS
   2. MARKET TRENDS This Chapter is Available Only for the Professional EditionPRO

3. 3. MARKET OVERVIEW

   Understanding the Current State of The Market and its Prospects

   1. MARKET SIZE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   2. CONSUMPTION BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   3. MARKET FORECAST TO 2035

4. 4. MOST PROMISING PRODUCTS FOR DIVERSIFICATION

   Finding New Products to Diversify Your Business

   • This Chapter is Available Only for the Professional EditionPRO
   1. TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
   2. BEST-SELLING PRODUCTS
   3. MOST CONSUMED PRODUCTS
   4. MOST TRADED PRODUCTS
   5. MOST PROFITABLE PRODUCTS FOR EXPORT

5. 5. MOST PROMISING SUPPLYING COUNTRIES

   Choosing the Best Countries to Establish Your Sustainable Supply Chain

   • This Chapter is Available Only for the Professional EditionPRO
   1. TOP COUNTRIES TO SOURCE YOUR PRODUCT
   2. TOP PRODUCING COUNTRIES
   3. TOP EXPORTING COUNTRIES
   4. LOW-COST EXPORTING COUNTRIES

6. 6. MOST PROMISING OVERSEAS MARKETS

   Choosing the Best Countries to Boost Your Export

   • This Chapter is Available Only for the Professional EditionPRO
   1. TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
   2. TOP CONSUMING MARKETS
   3. UNSATURATED MARKETS
   4. TOP IMPORTING MARKETS
   5. MOST PROFITABLE MARKETS

7. 7. PRODUCTION

   The Latest Trends and Insights into The Industry

   1. PRODUCTION VOLUME AND VALUE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   2. PRODUCTION BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)

8. 8. IMPORTS

   The Largest Import Supplying Countries

   1. IMPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   2. IMPORTS BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   3. IMPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)

9. 9. EXPORTS

   The Largest Destinations for Exports

   1. EXPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   2. EXPORTS BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   3. EXPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)

10. 10. PROFILES OF MAJOR PRODUCERS

    The Largest Producers on The Market and Their Profiles

    • This Chapter is Available Only for the Professional EditionPRO

11. 11. COUNTRY PROFILES

    The Largest Markets And Their Profiles

    This Chapter is Available Only for the Professional EditionPRO

12. LIST OF TABLES

    1. Key Findings In 2025
    2. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    3. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
    4. Per Capita Consumption, by Country, 2022–2025
    5. Production, In Physical Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    6. Imports, In Physical Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    7. Imports, In Value Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    8. Import Prices, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    9. Exports, In Physical Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    10. Exports, In Value Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    11. Export Prices, By Country: Historical Data (2012–2025) and Forecast (2026–2035)

13. LIST OF FIGURES

    1. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    2. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
    3. Consumption, by Country, 2025
    4. Market Volume Forecast to 2035
    5. Market Value Forecast to 2035
    6. Market Size and Growth, By Product
    7. Average Per Capita Consumption, By Product
    8. Exports and Growth, By Product
    9. Export Prices and Growth, By Product
    10. Production Volume and Growth
    11. Exports and Growth
    12. Export Prices and Growth
    13. Market Size and Growth
    14. Per Capita Consumption
    15. Imports and Growth
    16. Import Prices
    17. Production, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    18. Production, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    19. Production, by Country, 2025
    20. Production, In Physical Terms, by Country: Historical Data (2012–2025) and Forecast (2026–2035)
    21. Imports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    22. Imports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    23. Imports, In Physical Terms, By Country, 2025
    24. Imports, In Physical Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    25. Imports, In Value Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    26. Import Prices, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    27. Exports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    28. Exports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    29. Exports, In Physical Terms, By Country, 2025
    30. Exports, In Physical Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    31. Exports, In Value Terms, By Country: Historical Data (2012–2025) and Forecast (2026–2035)
    32. Export Prices, By Country: Historical Data (2012–2025) and Forecast (2026–2035)

Recommended posts

Market Intelligence

Free Data: Insights – United States

Instant access. No credit card needed

Sign in for free